A phase I study of hepatic arterial infusion using difluoromethylornithine

Cancer. 1989 Feb 1;63(3):433-7. doi: 10.1002/1097-0142(19890201)63:3<433::aid-cncr2820630306>3.0.co;2-5.

Abstract

Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Drug Evaluation
  • Eflornithine / administration & dosage
  • Eflornithine / adverse effects
  • Eflornithine / therapeutic use*
  • Hearing Loss, Bilateral / chemically induced
  • Hepatic Artery*
  • Humans
  • Infusions, Intra-Arterial
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Middle Aged

Substances

  • Eflornithine